Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SoftOx Solutions AS ( (DE:6FV) ) has shared an announcement.
SoftOx Solutions AS has submitted a clinical trial application to the Danish Medicines Agency for a Phase 2a clinical study of its inhalation solution for cystic fibrosis. This marks a significant milestone in their clinical development strategy, with the potential to address unmet medical needs and target a market of over USD 600 million in the US and Europe. The study, expected to start in Q1 2026, could also lead to expansion into related indications and enhance SoftOx’s appeal to global pharmaceutical partners.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. It develops highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, based on research and development in collaboration with leading Nordic research institutes.
YTD Price Performance: 442.86%
Average Trading Volume: 18,257,421
Current Market Cap: NOK178.2M
For detailed information about 6FV stock, go to TipRanks’ Stock Analysis page.